自体造血干细胞移植治疗弥漫大B细胞淋巴瘤临床分析

摘要

The purpose of this study was to investigate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL),and analyse the factors influencing prognosis.The clinical data of 67 patients with DLBCL received auto-HSCT from 1996 to 2011 and cumulative overall survival (OS),progression-free survival (PFS),transplant-related mortality (TRM),and relapse rate were retrospectively analyzed.The results showed that the median follow-up time was 40 months after transplantation.Three-year cumulative OS and PFS were 70.6％ and 66.4％ respectively,5-year cumulative OS and PFS were 70.6％ and 63.8％ respectively,and TRM was 7.2％.One-year and three-year cumulative relapse rate were 16.5％ and 23.7％ respectively.Univariate analysis revealed that the age and pre-transplant disease status were significantly associated with poor prognosis (P ＜ 0.05).It is concluded that auto-HSCT is a safe and effective therapeutic option for patients with DLBCL,especially for the young patients or patients with better remission.%本研究探讨自体造血干细胞移植(autologous hematopoietic stem cell transplantation,auto-HSCT)治疗弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)疗效及预后影响因素.回顾性分析本院1996-2011年67例DLBCL患者行auto-HSCT临床资料,观察生存结果并分析预后影响因素.结果表明,随访时间截至2012年11月1日,移植后中位随访时间40(1-197)个月,3年总体生存(overall survival,OS)和无进展生存(progression-free survival,PFS)分别为70.6％和66.4％,5年OS和PFS分别为70.6％和63,8％.移植相关死亡率(transplant-related mortality,TRM)为7.2％,1年和3年累计复发率分别为16.5％和23.7％.单因素分析显示,患者年龄和移植前疾病状态是DLBCL患者auto-HSCT后长期生存的显著影响因素.结论:auto-HSCT治疗弥漫大B细胞淋巴瘤安全有效,年轻、移植前肿瘤负荷低的患者预后更好.